Nanoemulsions are a type of emulsion that have a droplet size of less than 100 nanometers. They are typically made by mixing two immiscible liquids, such as oil and water, with the help of a surfactant. Nanoemulsions have a number of advantages over traditional emulsions, including increased stability, clarity, and bioavailability.

In recent years, nanoemulsions have been increasingly explored for use as vaccine delivery systems. This is due to the fact that nanoemulsions can improve the stability of vaccines, protect them from degradation, and target them to specific cells or tissues.

Several nanoemulsion-based vaccines are currently in clinical trials or have been approved for use. For example, the NanoFlu vaccine, which is approved for use in Europe, is a nanoemulsion-based influenza vaccine that has been shown to be more effective than traditional influenza vaccines.

Other nanoemulsion-based vaccines that are in development include vaccines for HIV, malaria, and tuberculosis. These vaccines are still in the early stages of development, but they show great promise for improving the prevention and treatment of these diseases.

In addition to their potential as vaccine delivery systems, nanoemulsions are also being explored for use in other biomedical applications, such as drug delivery, gene therapy, and tissue engineering. Nanoemulsions offer a number of advantages over traditional drug delivery systems, including increased bioavailability, reduced toxicity, and targeted delivery.

As research continues, nanoemulsions are likely to play an increasingly important role in the development of new and improved vaccines and other biomedical therapies.